Smith Group Asset Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Smith Group Asset Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,270	Closed	-$19K	–	457
2019 Q2	$19K	Hold	1,270	–	–	﹤0.01%	335
2019 Q1	$32K	Sell	1,270 -4,400	-78%	-$110K	﹤0.01%	338
2018 Q4	$102K	Sell	5,670 -500	-8%	-$10.2K	﹤0.01%	281
2018 Q3	$181K	Buy	6,170 +1,620	+36%	+$62.7K	0.01%	253
2018 Q2	$207K	Buy	4,550 +100	+2%	+$4.86K	0.01%	250
2018 Q1	$235K	Sell	4,450 -3,600	-45%	-$210K	0.01%	238
2017 Q4	$547K	Hold	8,050	–	–	0.02%	202
2017 Q3	$663K	Hold	8,050	–	–	0.02%	193
2017 Q2	$754K	Buy	8,050 +1,210	+18%	+$74K	0.02%	175
2017 Q1	$436K	Hold	6,840	–	–	0.01%	196
2016 Q4	$304K	Buy	+6,840	New	+$241K	0.01%	222
2015 Q4	–	Sell	-8,030	Closed	-$738K	–	521
2015 Q3	$738K	Sell	8,030 -51	-0.6%	-$4.41K	0.03%	182
2015 Q2	$706K	Buy	+8,081	New	+$692K	0.02%	184

Other funds holding CLVS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Smith Group Asset Management's CLVS Position: Q3 2019 in Review

Smith Group Asset Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2019, closing a stake of 1,270 shares — an estimated $19K sold.

Smith Group Asset Management first reported a position in CLVS in Q2 2015 and held it in 13 quarters. The position peaked at $754K in Q2 2017. 153 funds tracked by Wall St. Rank hold CLVS as of Q3 2019.

Smith Group Asset Management reported no remaining Clovis Oncology, Inc. position as of Q3 2019 after selling out during the quarter.
Smith Group Asset Management sold 1,270 Clovis Oncology, Inc. shares in Q3 2019, an estimated $19K.
Smith Group Asset Management first reported a position in Clovis Oncology, Inc. in Q2 2015 and held it in 13 quarters.
Smith Group Asset Management's Clovis Oncology, Inc. position peaked at $754K in Q2 2017.
153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2019.

Based on Smith Group Asset Management's 13F filing for Q3 2019, filed 12 Nov 2019.